LB Pharmaceuticals Appoints New CFO Joseph M. Miller

What Happened
LB Pharmaceuticals Inc. announced that Joseph M. Miller (age 52) has been appointed Chief Financial Officer, effective September 2, 2026. Mr. Miller joins from Aurinia Pharmaceuticals (CFO from April 2020–March 2026) and has more than two decades of finance experience in biotech and pharmaceutical companies. The company disclosed the material terms of an employment agreement and issued a press release on September 3, 2026 (Exhibit 99.1).

Key Details

• Base salary: $530,000 per year; Target discretionary bonus: 40% of base salary.
• Equity: Option to purchase 200,000 shares (inducement grant under Nasdaq Rule 5635(c)(4)), vesting over four years (25% at 1 year, then monthly).
• Severance: If terminated without cause or resigns for good reason within 3 months before to 12 months after a change of control — lump sum = 1 year base salary + 150% of Target Bonus, COBRA up to 12 months, and full acceleration of unvested equity. Outside that period — nine months salary continuation and COBRA up to nine months.
• Other terms: at‑will employment, standard employee benefits, confidentiality and 12‑month non‑solicit covenant, indemnification agreement to be entered.

Why It Matters
This 8-K signals a material leadership change at LB Pharmaceuticals with a seasoned biotech finance executive taking the CFO role. Key compensation elements (salary, bonus target, 200k-option grant and severance protections) affect potential future dilution, cash compensation costs and governance alignment. The inducement option grant and change‑of‑control severance terms are typical but important to note for investors tracking executive incentives and potential costs tied to leadership transitions. The company also furnished a press release announcing the appointment.